{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:07:28Z","timestamp":1792098448982,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"25","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,25]],"date-time":"2019-12-25T00:00:00Z","timestamp":1577232000000},"content-version":"vor","delay-in-days":389,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.jacc.2018.09.076","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T16:01:12Z","timestamp":1545062472000},"page":"3246-3254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes"],"prefix":"10.1016","volume":"72","author":[{"given":"Anahita","family":"Ghorbani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijeta","family":"Bhambhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Christenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer E.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2018.09.076_bib1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/eurjhf\/hfp097","article-title":"Galectin-3: a novel mediator of heart failure development and progression","volume":"11","author":"de Boer","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2018.09.076_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11897-010-0004-x","article-title":"Galectin-3 in cardiac remodeling and heart failure","volume":"7","author":"de Boer","year":"2010","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jacc.2018.09.076_bib3","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2018.09.076_bib4","doi-asserted-by":"crossref","first-page":"H404","DOI":"10.1152\/ajpheart.00747.2008","article-title":"N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion\/growth-regulatory lectin","volume":"296","author":"Liu","year":"2009","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jacc.2018.09.076_bib5","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","article-title":"Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis","volume":"6","author":"Yu","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2018.09.076_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijcard.2014.12.137","article-title":"Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis","volume":"182","author":"Chen","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.09.076_bib7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.ahj.2013.12.031","article-title":"Galectin-3 is independently associated with cardiovascular mortality in community-dwelling older adults without known cardiovascular disease: The Rancho Bernardo Study","volume":"167","author":"Daniels","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2018.09.076_bib8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/CIRCHEARTFAILURE.112.000129","article-title":"Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH","volume":"6","author":"van der Velde","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2018.09.076_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2796.2011.02476.x","article-title":"The fibrosis marker galectin-3 and outcome in the general population","volume":"272","author":"de Boer","year":"2012","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jacc.2018.09.076_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1373\/clinchem.2011.174359","article-title":"Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22","volume":"58","author":"Grandin","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacc.2018.09.076_bib11","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.21","article-title":"Plasma galectin 3 and heart failure risk in the Physicians' Health Study","volume":"16","author":"Djousse","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2018.09.076_bib12","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2012.04.053","article-title":"Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community","volume":"60","author":"Ho","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2018.09.076_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijcard.2015.05.040","article-title":"Predictive value of galectin-3 for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort","volume":"192","author":"Jagodzinski","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.09.076_bib14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ahj.2013.02.029","article-title":"Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results","volume":"165","author":"Wu","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2018.09.076_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/ejhf.669","article-title":"Variability of biomarkers in patients with chronic heart failure and healthy controls","volume":"19","author":"Meijers","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2018.09.076_bib16","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1136\/heartjnl-2015-308975","article-title":"Serial galectin-3 and future cardiovascular disease in the general population","volume":"102","author":"van der Velde","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2018.09.076_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijcard.2016.07.241","article-title":"Determinants of temporal changes in galectin-3 level in the general population: Data of PREVEND","volume":"222","author":"van der Velde","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2018.09.076_bib18","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/eurjhf\/hft075","article-title":"Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study","volume":"15","author":"Motiwala","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2018.09.076_bib19","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1093\/eurjhf\/hfs205","article-title":"Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT","volume":"15","author":"Anand","year":"2013","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2018.09.076_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/oxfordjournals.aje.a112813","article-title":"An investigation of coronary heart disease in families. The Framingham offspring study","volume":"110","author":"Kannel","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jacc.2018.09.076_bib21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.clinbiochem.2010.02.001","article-title":"Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure","volume":"43","author":"Christenson","year":"2010","journal-title":"Clin Biochem"},{"key":"10.1016\/j.jacc.2018.09.076_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cca.2017.11.018","article-title":"One-year in\u00a0vitro stability of cardiac troponins and galectin-3 in different sample types","volume":"476","author":"Egger","year":"2018","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jacc.2018.09.076_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A\u00a0more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2018.09.076_bib25","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMoa031994","article-title":"Plasma natriuretic peptide levels and the risk of cardiovascular events and death","volume":"350","author":"Wang","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.076_bib26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJM197112232852601","article-title":"The natural history of congestive heart failure: the Framingham study","volume":"285","author":"McKee","year":"1971","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2018.09.076_bib27","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.kint.2017.06.028","article-title":"Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease","volume":"93","author":"Rebholz","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2018.09.076_bib28","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1681\/ASN.2012090909","article-title":"Elevated galectin-3 precedes the development of CKD","volume":"24","author":"O'Seaghdha","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2018.09.076_bib29","first-page":"59","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2018.09.076_bib30","doi-asserted-by":"crossref","first-page":"e002347","DOI":"10.1161\/JAHA.115.002347","article-title":"Circulating galectin-3 is associated with cardiometabolic disease in the community","volume":"5","author":"Nayor","year":"2015","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2018.09.076_bib31","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/HYPERTENSIONAHA.115.05876","article-title":"Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension","volume":"66","author":"Martinez-Martinez","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2018.09.076_bib32","doi-asserted-by":"crossref","first-page":"593","DOI":"10.7150\/thno.22196","article-title":"Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update","volume":"8","author":"Suthahar","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jacc.2018.09.076_bib33","doi-asserted-by":"crossref","first-page":"e003079","DOI":"10.1161\/JAHA.115.003079","article-title":"Galectin-3 and risk of heart failure and death in blacks and whites","volume":"5","author":"McEvoy","year":"2016","journal-title":"J\u00a0Am Heart Assoc"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971838906X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S073510971838906X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:18:32Z","timestamp":1760015912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S073510971838906X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":32,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S073510971838906X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2018.09.076","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734676713.793583498","asserted-by":"object"}]},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Longitudinal Change in Galectin-3 and Incident Cardiovascular Outcomes","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2018.09.076","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}